Moexipril and arterial hypertension treatment in postmenopausal women

Abstract

Aim. To assess effectiveness of ACE inhibitor moexipril (Moex®) in postmenopausal women with arterial hypertension (AH). Material and methods. In total, 50 women were examined; mean age 64.1±0.9 years, mean AH duration – 10.1±2.5 years. Moexipril treatment in daily dose 7.5-15 mg lasted for 12 weeks. Office blood pressure (BP), autonomous dysbalance symptoms (questionnaire on autonomous disturbances and hyperventilation syndrome), night sleep disturbances (questionnaire on subjective sleep disturbances), reactive and personal anxiety (RA, PA; Spielberger scale), depression (Zung test), quality of life (QoL; WHO questionnaire QoL-100) were assessed. Results. By the end of moexipril treatment, target BP levels were achieved for 76.5% of the patients. Vegetative symptoms, sleep quality, RA and depression parameters significantly improved (р<0.5). Moexipril therapy was associated with QoL improvement by 5.2%. Conclusion. Moexipril demonstrated antihypertensive effects as well as autonomous balance and QoL improvement in postmenopausal women with AH.